| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 73 | 14.7x | 17.8x | Top tier | |
Growth | 34 | 6.5% | 7.1% | Bottom tier | |
Quality | 61 | 10.1% | 4.5% | Around median | |
Safety | 54 | 2.4x | 2.6x | Around median | |
Capital Return | 36 | 0.22% | 2.12% | Bottom tier | |
Momentum | 32 | -6.7% | 2.9% | Bottom tier | |
Sentiment | 84 | 12 | 3 | Top tier |
Estimates — analyst targets and a simplified DCF, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
GE HealthCare Technologies operates through three interconnected segments: Advanced Imaging Solutions, which includes technologies such as CT, MR, molecular imaging, ultrasound, and interventional platforms; Pharmaceutical Diagnostics, which sells contrast agents and diagnostic radiopharmaceuticals; and Patient Care Solutions, which includes patient monitoring and anesthesia systems. The company also generates recurring revenue from equipment maintenance, services, software agreements, and AI-enabled subscriptions, including the True Definition DL upgrade for customers’ installed CT systems.
In Q2 fiscal 2026, revenue reached $5.3 billion, with organic growth of 3.5% year over year, while product and service revenue grew 4.7% and 7.7%, respectively. Adjusted operating profit was $750 million, and its margin reached 14.2%, down 40 basis points, while adjusted earnings per share increased 6.6% to $1.13; the result included $0.04 from tariff refunds and $0.02 from a lower tax rate. Free cash flow was $68 million, including $107 million in tariff refunds.
The segment mix showed a clear divergence in Q2 fiscal 2026: Advanced Imaging Solutions organic revenue grew 5%, and its operating margin increased 90 basis points, while Pharmaceutical Diagnostics organic revenue jumped 14.6%, with an operating margin of 29.6%, up 30 basis points. In contrast, Patient Care Solutions organic revenue declined 13.5%, and the segment recorded an operating loss due to supply and execution difficulties. Combined, Advanced Imaging Solutions and Pharmaceutical Diagnostics grew by approximately 6.5% and expanded margin by 100 basis points year over year.
The average analyst price target is $78.73, within a wide range of $65 to $90, with a consensus rating of “Buy.” The average target is approximately 12% below the 52-week range high of $89.77, while the highest target of $90 nearly matches that high, and the lowest target of $65 remains closer to the range low of $58.75. This dispersion reflects the market’s balancing of the record backlog and Pharmaceutical Diagnostics growth on one hand, against weakness in Patient Care Solutions and inflationary pressure on margins on the other.
Figures in the text are as of 2026-08-28; the live price is shown at the top of the page.
GE HealthCare generated revenue of $5.3 billion and organic growth of 3.5% in Q2 fiscal 2026. Growth was led by Pharmaceutical Diagnostics, which grew organically by 14.6%, and Advanced Imaging Solutions, which grew by 5%. Adjusted operating profit was $750 million at a margin of 14.2%, and adjusted earnings per share increased 6.6% to $1.13. The 13.5% decline in Patient Care Solutions revenue limited the strength of the overall results.
The backlog reached $23.9 billion in Q2 fiscal 2026, up $2.6 billion from the corresponding period and $2.1 billion from the previous quarter. This was accompanied by organic order growth of 11.1% and a book-to-bill ratio of 1.15 times, both at their highest levels since the company’s spin-off. Approximately one-quarter of the sequential increase was related to product orders, while the remainder was linked to multiyear service agreements that convert into revenue gradually. Management expects longer-cycle imaging product orders to convert into revenue more visibly during fiscal 2027.
The Pharmaceutical Diagnostics business is benefiting from increased use of disease-specific radiopharmaceuticals. Vizamyl achieved double-digit revenue growth during Q2 fiscal 2026 as adoption of amyloid therapies expanded, while DaTscan and Cerianna products also recorded strong growth. Weekly Flyrcado doses reached 545 doses in the week ended July 24, 2026, an increase of approximately 40% from April 2026. Management reaffirmed its target of $500 million or more in annual Flyrcado revenue by fiscal 2028.
Automated analysis for informational purposes only — not investment advice.
Patient Care Solutions organic revenue declined 13.5% in Q2 fiscal 2026, and the segment recorded an operating loss. Management attributed this to execution difficulties in fulfilling orders and shortages of certain critical components, which delayed shipments of monitoring and anesthesia products. In contrast, the segment recorded strong order growth in the first half, and the company is targeting improved shipments, revenue, and margin during the second half of fiscal 2026. It is also reviewing strategic options that include continued ownership of the segment, a sale, or other transactions to enhance value.
The innovation cycle includes Photonova Spectra for photon-counting computed tomography, the Bolt 3T magnetic resonance platform, the Vivid Pioneer ultrasound system, and the deep-learning-enabled True Definition DL upgrade. The company expects to obtain CE marking for the Photonova Spectra platform in the second half of fiscal 2026, while its contribution to Q2 orders was limited, leaving most of its commercial impact for later periods. True Definition DL provides nearly twice the image resolution across the installed CT base and can be offered through a recurring subscription. Vivid Pioneer achieved a significantly higher gross margin than the previous platform due to lower manufacturing costs and the higher pricing value of its AI-enabled capabilities.
Management is targeting organic revenue growth of between 3% and 4% in fiscal 2026. It also expects adjusted operating profit margin expansion of between 10 and 40 basis points, reaching a range of 15.4%–15.7%, and adjusted earnings per share of between $4.80 and $5.00. The company entered Q3 fiscal 2026 with more than 80% and nearly 85% of expected equipment revenue secured. Achieving the guidance depends on backlog conversion, growth in Flyrcado and radiopharmaceuticals, stabilization of Patient Care Solutions, and the impact of pricing and cost actions emerging during the second half.
